EPIX Therapeutics
Founded Year
2007Stage
Acquired | AcquiredTotal Raised
$70MAbout EPIX Therapeutics
EPIX Therapeutics is a medical device company. It designs and manufactures a catheter-based system for the treatment of patients with cardiac arrhythmias and atrial fibrillation. EPIX Therapeutics was formerly known as Advanced Cardiac Therapeutics. The company was founded in 2007 and is based in Santa Clara, California. In Jan 2019, EPIX Therapeutics was acquired by Medtronic.
Missing: EPIX Therapeutics's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: EPIX Therapeutics's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing EPIX Therapeutics
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
EPIX Therapeutics is included in 2 Expert Collections, including Medical Devices.
Medical Devices
8,633 items
Companies developing medical devices (per the IMDRF's definition of "medical device"). Includes software, lab-developed tests (LDTs), and combination products. *Columns updated as regularly as possible.
Health IT
7,901 items
EPIX Therapeutics Patents
EPIX Therapeutics has filed 40 patents.
The 3 most popular patent topics include:
- Cardiac anatomy
- Cardiac arrhythmia
- Cardiac electrophysiology

Application Date | Grant Date | Title | Related Topics | Status |
---|---|---|---|---|
10/3/2019 | 5/9/2023 | Cardiac arrhythmia, Cardiac anatomy, Cardiac electrophysiology, Heart diseases, Syndromes affecting the heart | Grant |
Application Date | 10/3/2019 |
---|---|
Grant Date | 5/9/2023 |
Title | |
Related Topics | Cardiac arrhythmia, Cardiac anatomy, Cardiac electrophysiology, Heart diseases, Syndromes affecting the heart |
Status | Grant |
Latest EPIX Therapeutics News
Apr 14, 2023
Published April 14, 2023 Dive Brief: Medtronic is moving forward with plans to close the former Epix Therapeutics facility in California and has issued a notice that the entire 59-person workforce will be laid off by September. After acquiring Epix for $316 million in 2019, Medtronic began considering moving production of its DiamondTemp catheter to a facility in Ireland. Medtronic told employees of its plans to close the Sunnyvale facility during in-person meetings last year. The execution of those plans comes as Medtronic consolidates the decentralized manufacturing and supply chain system that it has identified as a drag on the business. Dive Insight: Medtronic bought Epix for a catheter-based, temperature-controlled cardiac ablation system designed to treat patients with irregular heartbeats including atrial fibrillation. Two years after making the deal, Medtronic received U.S. Food and Drug Administration approval for the device. To acquire DiamondTemp, Medtronic also had to take on Epix’s Sunnyvale facility and employees. Now, similar to 20 years ago when Medtronic bought PercuSurge and closed its Sunnyvale site, the company has decided to move on without Epix’s former facility and employees. “As we assess our business, we need to make longer-term structural changes to ensure the sustainability of our organization. We previously announced plans to close this facility and after careful analysis and consideration, we have made the necessary decision to close the site in June 2023, therefore eliminating some positions,” company spokesperson Erika Winkels said in an emailed statement. “Medtronic operates in a highly competitive environment and is continually taking actions to drive effectiveness and efficiencies to drive growth and position us for the future,” Winkels added. Karen Parkhill, Medtronic’s chief financial officer, told investors in February that the company was focused on delivering “significant expense reductions” as it navigates “macro headwinds from foreign currency and inflation.” Medtronic subsequently combined its robotic-assisted surgery technology and older surgical devices into a single operating unit.
EPIX Therapeutics Frequently Asked Questions (FAQ)
When was EPIX Therapeutics founded?
EPIX Therapeutics was founded in 2007.
Where is EPIX Therapeutics's headquarters?
EPIX Therapeutics's headquarters is located at 2880 Lakeside Drive, Santa Clara.
What is EPIX Therapeutics's latest funding round?
EPIX Therapeutics's latest funding round is Acquired.
How much did EPIX Therapeutics raise?
EPIX Therapeutics raised a total of $70M.
Who are the investors of EPIX Therapeutics?
Investors of EPIX Therapeutics include Medtronic, New Enterprise Associates, Questa Capital, Ajax Health, NBGI Ventures and 3 more.
Who are EPIX Therapeutics's competitors?
Competitors of EPIX Therapeutics include NeoChord, Ultrasound Medical Devices, Cardiac Science Corporation, Mirabilis, CardioInsight Technologies and 11 more.
Compare EPIX Therapeutics to Competitors
ES Vascular Ltd. developed first ever surgical stapling devices for endovascular surgery. These devices aim to transform vascular surgery by shortening procedural times, and by simplifying and potentially increasing the safety of the most common vascular interventions. The company is currently developing three product lines for open AAA, endovascular AAA and Femoro-Pop bypass procedures. Its first products are anticipated to enter the market in 2008.nCompany Snapshotn Started in 2000 in Israel by Prof. Shifrin together with group of engineers and leading vascular surgeons from the US and Europe;n Developed a ever vascular stapling technology for stapling synthetic grafts to the aortan Developed endovascular devices for EVAR and SFA procedures
MediGuide is a medical-device company developing tracking and imaging technologies for use during minimally-invasive surgical procedures. Located in Haifa, Israel, MediGuide was established in 2001 as a spin-off of Elbit Systems (NASDAQ: ESLT), a major Israeli defense technology company. MediGuide has developed a highly sophisticated navigation system: Medical Positioning System ("gMPS"), which is aimed to enable real-time tracking of therapeutic and future diagnostic medical devices (gMPS Enabled Devices) such as catheters and stents equipped with miniature gMPS sensors. gMPS is intended to provide clinicians with 3-D information about the structure of the coronary arteries and to track gMPS-enabled devices in these vessels.

OrthoScan, Inc. manufactures the OrthoScan High Definition Mini C-Arm for extremity imaging. Designed for orthopedic surgeons, the small, lightweight C-arm configuration fluoroscopic system aims to provide real-time images with four times the resolution of other currently available fluoroscans. It can be used during surgical orthopedic procedures, and critical and emergency care procedures. OrthoScan, headquartered in Scottsdale, Arizona, uses state-of-the-art technologies to bring x-ray imaging in extremity surgery to a next level. For instance, innovative flat detectors in the latest product introduction named OrthoScan HD, allows reduction of distortions inherent with previous image intensifier technology, thereby improving significantly diagnostic accuracy. The mini C-Arms by OrthoScan provide the solution needed by orthopaedics and podiatrists for high-quality imaging in a small-scale device, facilitating complex surgeries on small and delicate body structures, such as wrists, knees and ankles. In September 2011, Orthoscan was acquired Aton, a German private investment firm. Orthoscan's valuation was not disclosed.
VasoLux MicroSystems, LLC has developed a diagnostic imaging system to help surgeons identify later-stage osteoarthritis patients who are best suited for cartilage repair procedures or joint replacement surgery.
CardioMag Imaging (CMI) is a medical device company that is engaged in the development and commercialization of a kind of cardiac diagnostic device known as MagnetoCardioGraphs (MCG). The device the company has developed consists of the integration of highly sophisticated sensors, electronics, and software. The company's MCG system is a non-invasive cardiac medical diagnostic device that aims to provide clinically relevant information about heart function without use of ionizing radiation. CardioMag's MCG system is a MCG system to obtain FDA approval.
Rafael Medical has developed a novel anchoring system for safely implanting and retrieving a wide range of intra-vascular devices in a minimally invasive manner. Based on the technology, diagnostic and therapeutic devices can be delivered into small and large blood vessels alike by way of a small-sized delivery system. Following the completion of the SafeFlo Filter the company is now developing additional devices geared to the interventional cardiology market.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.